Print Page  Close Window

2018 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015
12/03/18
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study
Topline results for the Phase III MicroStat Program for pharmacologic mydriasis expected H1 2019 NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) today announced that it has completed patient enrollment in its Phase III MIST-1 study and enrolled the first patient in its second Phase III study, the MIST-2 trial, for the Company’s Phase III MicroStat program for pharmacologic mydriasis, or dilation of the pupil for an eye exam. Dr. Sean Ianchulev, Eyenovia’s Chief Ex... 
11/28/18
Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability
Almost 90% ocular delivery success with high-precision smart micro-dosing sets new benchmark for topical instillation to the eye NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) today announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-review journal ... 
11/26/18
Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study
Topline results for Phase III MicroStat program expected H1 2019 NEW YORK, Nov. 26, 2018 /PRNewswire/ -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has enrolled the first patient in the first of two Phase III trials (MIST-1 and MIST-2) of the Company's MicroStat program for pharmacologic mydriasis, or dilation of the pupil for an ey... 
11/13/18
Eyenovia Announces FDA Acceptance of MicroStat IND Application for Mydriasis
Company on track to initiate Phase III trials in late November NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-dosed medications topically to the eye, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application to initiate Phase III trials of MicroStat for... 
11/13/18
Eyenovia Reports Third Quarter 2018 Financial Results
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced financial results for the third quarter ended September 30, 2018. Q3 2018 and Recent Business Highlights Received investigational new drug (IND) acceptance to enter Phase III with MicroStat for mydriasis Results from P... 
11/01/18
Eyenovia Announces Conference Call and Webcast for Third Quarter 2018 Financial Results
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that the Company will release financial results for the third quarter ended September 30, 2018 on Tuesday, November 13, 2018, before the market opens. Following the release, Dr. Sean Ianchulev, President and Chief Executive Offic... 
10/23/18
Eyenovia to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2018
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer, will present data from the Company’s PG21 study at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (AAO) 2018 tak... 
09/19/18
Eyenovia to Participate in Panel Presentation at OSN New York 2018
CEO Sean Ianchulev to join industry panel discussion on “Medical and Surgical Management of Corneal Conditions and Complications” NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer, has been i... 
09/18/18
Eyenovia to Present at the Ladenburg Thalmann 2018 Healthcare Conference
NEW YORK, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer, is scheduled to present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018 at The Sofitel New York Hotel. Details of ... 
08/21/18
Eyenovia to Present at the 20th Annual H.C. Wainwright Global Investment Conference
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer, is scheduled to present at the 20th Annual H.C. Wainwright Global Investment Conference taking place on September 4-6, 2018 at The St. Regis N... 
08/14/18
Eyenovia Reports Second Quarter 2018 Financial Results
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced financial results for the second quarter ended June 30, 2018. 2Q 2018 Business Highlights EYN PG21 trial results demonstrated robust intraocular pressure lowering and patient usability; Received notice of allowance fro... 
08/13/18
Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability
Positive results validate Eyenovia’s piezo-print technology for topical eye treatment as Company prepares for Phase III trials in progressive myopia, CACG and mydriasis NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced positive results of its EYN PG21 proof-of-concept study of ... 
07/31/18
Eyenovia Announces Conference Call and Webcast for Second Quarter 2018 Financial Results
NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that the Company will release financial results for the second quarter ended June 30, 2018 on Tuesday, August 14, 2018, before the market opens. Following the release, Dr. Sean Ianchulev, President and Chief Executive O... 
07/09/18
Eyenovia Appoints Michael Rowe as Vice President of Marketing Ahead of Initiation of Multiple Phase III Programs
NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the appointment of Michael Rowe as Vice President of Marketing. Mr. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the U.S. and globally acro... 
06/11/18
Eyenovia to Present at the JMP Securities 2018 Life Sciences Conference
NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer is scheduled to present at the JMP Securities 2018 Life Sciences Conference taking place on June 20-21, 2018 at The St. Regis New York. Details of the prese... 
06/05/18
Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Delivery
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for two additional patent applications. The allowed patents provide fundamental coverage on physiologic microdroplet ejection diamet... 
05/09/18
Eyenovia Reports First Quarter 2018 Financial Results and Completion of EYN PG21 Study
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced financial results for the first quarter ended March 31, 2018. 1Q 2018 Business Highlights Raised $24.5 million in net proceeds from initial public offering in January 2018; Completed EYN PG21 study demonstrati... 
04/19/18
Eyenovia Announces Conference Call and Webcast for First Quarter 2018 Financial Results
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that the Company will release financial results for the first quarter ended March 31, 2018 on Wednesday, May 9, 2018, before the market opens. Following the release, Dr. Sean Ianchulev, President and Chief Executive Of... 
04/02/18
Eyenovia Announces Fourth Quarter and Full Year 2017 Financial Results
Successfully Completed EYN PG21 Study Evaluating Usability and IOP Lowering with Micro-Therapeutic Latanoprost NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced financial results for the fourth quarter and full year ended December 31, 2017. Recent Business Highlig... 
03/26/18
Eyenovia Appoints Three Industry Veterans to Board of Directors
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that it has appointed directors Kenneth B. Lee, Jr., Charles E. Mather IV and Anthony Y. Sun, as independent members of its Board of Directors, effective immediately. Mr. Lee will serve as Chairman of the Audit Comm... 
03/19/18
Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full Year 2017 Financial Results
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, announced today that the Company will release financial results for the fourth quarter and full year ended December 31, 2017 on Monday, April 2, 2018, before the market opens. Following the release, Dr. Sean Ianchulev, Pre... 
02/27/18
Eyenovia to Present at the 30th Annual ROTH Conference
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer is scheduled to present at the 30th Annual ROTH Conference taking place on March 11-13, 2018 at The Ritz-Carlton in Dana Point, California. Deta... 
02/21/18
Eyenovia Advances MicroPine for Myopia into Phase III Clinical Development and Appoints Stanford Professor Dr. Douglas Fredrick to its Scientific Advisory Board and Myopia Program Steering Committee
NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye,  today announced that following discussions with the U.S. Food and Drug Administration (FDA), it has received clear feedback on its pivotal trial protocol design, as well as confirmation to advance its MicroPine therapeuti... 
01/29/18
Eyenovia Announces Closing of $27.3 Million Initial Public Offering
NEW YORK, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. (“Eyenovia”), (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the closing of its initial public offering of 2,730,000 shares of its common stock. Eyenovia received $27.3 million in gross proceeds from the offering, before underwriting discounts and commissions and oth... 
01/25/18
Eyenovia Announces Pricing of Initial Public Offering
NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Eyenovia Inc. ("Eyenovia"), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the pricing of its initial public offering of 2,730,000 shares of common stock at a price of $10.00 per share. In addition, Eyenovia has granted the underwriters a 30-day option to purchase up to an additional 409,500 share... 
01/09/18
Eyenovia Announces Appointment of John Gandolfo as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Eyenovia Inc., a clinical-stage ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class micro-therapeutics for the eye, today announced the appointment of John Gandolfo as Chief Financial Officer (CFO) effective December 18, 2017.Mr. Gandolfo has more than 30 years of experience in executive and senior management positions with high growth public and private companies, primarily in the medical devices and life sc...